Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dajisu (dyclonine hydrochloride mucilage) is a topical anesthetic gel developed and manufactured by Yangzijiang Pharmaceutical Group. Its active ingredient, dyclonine hydrochloride, is a ketone-based small molecule local anesthetic that works by blocking voltage-gated sodium channels on neuronal membranes, thereby inhibiting the initiation and conduction of nerve impulses. Dajisu is specifically indicated for providing local anesthesia and lubrication of the throat and upper gastrointestinal tract during endoscopy procedures. Additionally, the formulation possesses mucolytic properties that help remove foam from the gastric cavity, enhancing visualization for the clinician. It was approved by the NMPA in China in 2004 and has been commercially available since 2005.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dajisu.